IP Library Granted Patent US 12,161,869
Granted Patent B2
US 12,161,869 · App. 18/140,387 · Granted Dec 10, 2024

Treatment of disorders associated with inflammation

Inventors: Margarita J. Vervoordeldonk (Maarssen, NL); Eric Irwin (Collegeville, PA); Daniel John Chew (Middlesex, GB); Matteo Donega (Middlesex, GB); Cindy Cleypool (Middlesex, GB); Isha Gupta (Middlesex, GB)
Assignee: Galvani Bioelectronics Limited
A61N1/3606A61N1/0556A61N1/36135A61N1/36139A61N1/3614A61N1/36171A61N1/36178A61N2001/083
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,161,869
App. No.
18/140,387
Granted
Dec 10, 2024
Kind
B2
Abstract

Stimulation of neural activity in a nerve supplying the spleen, wherein the nerve is adjacent to the splenic artery at a position where the splenic artery is not in direct contact with the pancreas, can modulate pro- and anti-inflammatory molecules levels, thereby reducing inflammation and providing ways of treating disorders, such as disorders associated with inflammation. The invention provides improved ways of reducing inflammation with minimized off-target effects, in particular surgical trauma.

Claims (24)

1. A system for stimulating the neural activity of a splenic arterial nerve in combination with an anti-inflammatory medicine, the system comprising:

at least one electrode in signaling contact with the nerve at a site where the splenic artery is not in direct contact with the pancreas; and

at least one controller electrically coupled to the at least one electrode, the at least one controller configured to control the operation of the least one electrode to apply an electrical signal to the nerve, wherein a charge density per phase applied to the nerve by the electrical signal is between 5 μC to 1100 μC per cm2 per phase,

wherein the electrical signal produces an improvement in a physiological parameter in a subject, and

wherein the improvement in the physiological parameter is one or more of a group consisting of: a reduction in a pro-inflammatory cytokine, an increase in an anti-inflammatory cytokine, an increase in a catecholamine, a change in an immune cell population, a change in an immune cell surface co-stimulatory molecule, a reduction in a factor involved in the inflammation cascade, a change in a level of an immune response mediator, and a decrease in splenic blood flow,

wherein the system is capable for use in combination with the anti-inflammatory medicine.

2. The system of claim 1 , wherein the site is a position of the splenic artery separated from the surface of the pancreas by a distance in a range of from 0.5 cm to 4 cm.

3. The system of claim 1 , wherein the site is at a splenic arterial loop.

4. The system of claim 1 , wherein the electrical signal comprises a pulse train, the pulse train comprising a plurality of pulses.

5. The system of claim 4 , wherein the pulses are charge-balanced and biphasic.

6. A method of reversibly stimulating neural activity in a nerve supplying the spleen, the method comprising:

providing the system of claim 1 ;

positioning at least one electrode in signaling contact with the nerve adjacent to a splenic arterial loop; and

controlling the operation of the least one electrode with at least one controller to apply an electrical signal to the nerve to reversibly stimulate neural activity, and

wherein the method is for treating a disorder associated with inflammation and further comprises use of an anti-inflammatory medicine.

7. The method of claim 6 wherein the anti-inflammatory medicine is a nonsteroidal anti-inflammatory drug, a steroid, a 5ASA, a disease modifying-anti-inflammatory drug or a biological drug.

8. The method of claim 6 wherein the anti-inflammatory medicine is a nonsteroidal anti-inflammatory drug.

9. The method of claim 6 wherein the anti-inflammatory medicine is a steroid.

10. The method of claim 6 wherein the anti-inflammatory medicine is a 5ASA.

11. The method of claim 6 wherein the anti-inflammatory medicine a disease modifying-anti-inflammatory drug (DMARDs).

12. The method of claim 11 wherein the DMARD is selected from the group consisting of azathioprine, methotrexate and cyclosporin.

13. The method of claim 11 wherein the DMARD is a Jak inhibitor.

14. The method of claim 6 wherein the anti-inflammatory medicine is a biological drug.

15. The method of claim 14 wherein the biological drug is infliximab or adalimumab.

Assignments (9)
CHANGE OF ADDRESS Recorded Apr 16, 2025
From: GALVANI BIOELECTRONICS LIMITED
To: GALVANI BIOELECTRONICS LIMITED
Reel/Frame 070854/0393 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2023
From: CLEYPOOL, CINDY
To: UNIVERSITAIR MEDISCH CENTRUM UTRECHT
Reel/Frame 063475/0566 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2023
From: UNIVERSITAIR MEDISCH CENTRUM UTRECHT
To: GALVANI BIOELECTRONICS LIMITED
Reel/Frame 063475/0602 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2023
From: DONEGA, MATTEO
To: GALVANI BIOELECTRONICS LIMITED
Reel/Frame 063475/0622 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2023
From: CHEW, DANIEL JOHN
To: GALVANI BIOELECTRONICS LIMITED
Reel/Frame 063475/0629 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2023
From: GUPTA, ISHA
To: GALVANI BIOELECTRONICS LIMITED
Reel/Frame 063475/0643 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2023
From: VERVOORDELDONK, MARGARITA J.
To: GALVANI BIOELECTRONICS LIMITED
Reel/Frame 063490/0291 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2023
From: IRWIN, ERIC
To: GALVANI BIOELECTRONICS INC.
Reel/Frame 063490/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 28, 2023
From: GALVANI BIOELECTRONICS INC.
To: GALVANI BIOELECTRONICS LIMITED
Reel/Frame 063490/0314 →
Continuity (4)
Continuation 17872432 · Jul 25, 2022
Continuation 16955393
Provisional Application 62608412 · Dec 20, 2017
Related Publication 20230271010A1 · Aug 31, 2023